These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11257479)

  • 1. Therapeutic options in ocular myasthenia gravis.
    Evoli A; Batocchi AP; Minisci C; Di Schino C; Tonali P
    Neuromuscul Disord; 2001 Mar; 11(2):208-16. PubMed ID: 11257479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term prednisone followed by thymectomy in myasthenia gravis.
    Mann JD; Johns TR; Campa JF; Muller WH
    Ann N Y Acad Sci; 1976; 274():608-22. PubMed ID: 1066998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
    Kupersmith MJ; Latkany R; Homel P
    Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Ocular Myasthenia Gravis.
    Cornblath WT
    Asia Pac J Ophthalmol (Phila); 2018; 7(4):257-259. PubMed ID: 30044061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of prednisone on the progression from ocular to generalized myasthenia gravis.
    Monsul NT; Patwa HS; Knorr AM; Lesser RL; Goldstein JM
    J Neurol Sci; 2004 Feb; 217(2):131-3. PubMed ID: 14706214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generalization after ocular onset in myasthenia gravis: a case series in Germany.
    Li F; Hotter B; Swierzy M; Ismail M; Meisel A; Rückert JC
    J Neurol; 2018 Dec; 265(12):2773-2782. PubMed ID: 30225725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myasthenia gravis: signs, symptoms, diagnosis, immunology, and current therapy.
    Scheife RT; Hills JR; Munsat TL
    Pharmacotherapy; 1981; 1(1):39-54. PubMed ID: 6927602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
    Benatar M; Kaminski HJ;
    Neurology; 2007 Jun; 68(24):2144-9. PubMed ID: 17460154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular myasthenia gravis: response to long-term immunosuppressive treatment.
    Sommer N; Sigg B; Melms A; Weller M; Schepelmann K; Herzau V; Dichgans J
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):156-62. PubMed ID: 9048716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myasthenia gravis.
    Silvestri NJ; Wolfe GI
    Semin Neurol; 2012 Jul; 32(3):215-26. PubMed ID: 23117946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular myasthenia: a protean disorder.
    Weinberg DA; Lesser RL; Vollmer TL
    Surv Ophthalmol; 1994; 39(3):169-210. PubMed ID: 7878520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed remission after thymectomy for myasthenia gravis of the purely ocular type.
    Nakamura H; Taniguchi Y; Suzuki Y; Tanaka Y; Ishiguro K; Fukuda M; Hara H; Mori T
    J Thorac Cardiovasc Surg; 1996 Aug; 112(2):371-5. PubMed ID: 8751505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and prognosis of myasthenia gravis in older people.
    Evoli A; Batocchi AP; Minisci C; Di Schino C; Tonali P
    J Am Geriatr Soc; 2000 Nov; 48(11):1442-8. PubMed ID: 11083321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective treatment of infantile myasthenia gravis by combined prednisone and thymectomy.
    Sarnat HB; McGarry JD; Lewis JE
    Neurology; 1977 Jun; 27(6):550-3. PubMed ID: 559263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocular aspects of myasthenia gravis.
    Barton JJ; Fouladvand M
    Semin Neurol; 2000; 20(1):7-20. PubMed ID: 10874773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive treatment of ocular myasthenia gravis.
    Tackenberg B; Hemmer B; Oertel WH; Sommer N
    BioDrugs; 2001; 15(6):369-78. PubMed ID: 11520248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects.
    Sommer N; Melms A; Weller M; Dichgans J
    Doc Ophthalmol; 1993; 84(4):309-33. PubMed ID: 8156854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical and surgical treatment for ocular myasthenia.
    Benatar M; Kaminski H
    Cochrane Database Syst Rev; 2006 Apr; (2):CD005081. PubMed ID: 16625623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children.
    Mullaney P; Vajsar J; Smith R; Buncic JR
    Ophthalmology; 2000 Mar; 107(3):504-10. PubMed ID: 10711889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppressive therapies in myasthenia gravis.
    Sanders DB; Evoli A
    Autoimmunity; 2010 Aug; 43(5-6):428-35. PubMed ID: 20166870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.